242 related articles for article (PubMed ID: 30385632)
1. Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.
Kim H; Yoo S; Zhou R; Xu A; Bernitz JM; Yuan Y; Gomes AM; Daniel MG; Su J; Demicco EG; Zhu J; Moore KA; Lee DF; Lemischka IR; Schaniel C
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):E11128-E11137. PubMed ID: 30385632
[TBL] [Abstract][Full Text] [Related]
2. Secreted Frizzled-Related Protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential.
Techavichit P; Gao Y; Kurenbekova L; Shuck R; Donehower LA; Yustein JT
BMC Cancer; 2016 Nov; 16(1):869. PubMed ID: 27821163
[TBL] [Abstract][Full Text] [Related]
3. Modeling familial cancer with induced pluripotent stem cells.
Lee DF; Su J; Kim HS; Chang B; Papatsenko D; Zhao R; Yuan Y; Gingold J; Xia W; Darr H; Mirzayans R; Hung MC; Schaniel C; Lemischka IR
Cell; 2015 Apr; 161(2):240-54. PubMed ID: 25860607
[TBL] [Abstract][Full Text] [Related]
4. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome.
Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M
Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821
[TBL] [Abstract][Full Text] [Related]
5. Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance.
Walia MK; Ho PM; Taylor S; Ng AJ; Gupte A; Chalk AM; Zannettino AC; Martin TJ; Walkley CR
Elife; 2016 Apr; 5():. PubMed ID: 27070462
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Wnt signaling by methylation-mediated loss of SFRP2 promotes osteosarcoma cell invasion.
Xiao Q; Yang Y; Zhang X; An Q
Tumour Biol; 2016 May; 37(5):6315-21. PubMed ID: 26628297
[TBL] [Abstract][Full Text] [Related]
7. Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells.
Zhou R; Xu A; Tu J; Liu M; Gingold JA; Zhao R; Lee DF
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985349
[TBL] [Abstract][Full Text] [Related]
8. Modeling of osteosarcoma with induced pluripotent stem cells.
Pang LK; Pena M; Zhao R; Lee DF
Stem Cell Res; 2020 Dec; 49():102006. PubMed ID: 33022533
[TBL] [Abstract][Full Text] [Related]
9. The crucial p53-dependent oncogenic role of JAB1 in osteosarcoma in vivo.
Samsa WE; Mamidi MK; Bashur LA; Elliott R; Miron A; Chen Y; Lee B; Greenfield EM; Chan R; Danielpour D; Zhou G
Oncogene; 2020 Jun; 39(23):4581-4591. PubMed ID: 32390003
[TBL] [Abstract][Full Text] [Related]
10. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
11. Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.
Lin YH; Jewell BE; Gingold J; Lu L; Zhao R; Wang LL; Lee DF
Trends Mol Med; 2017 Aug; 23(8):737-755. PubMed ID: 28735817
[TBL] [Abstract][Full Text] [Related]
12. Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors.
Habel N; Vilalta M; Bawa O; Opolon P; Blanco J; Fromigué O
Oncogene; 2015 Jun; 34(24):3207-13. PubMed ID: 25065593
[TBL] [Abstract][Full Text] [Related]
13. Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice.
Sabile AA; Arlt MJ; Muff R; Husmann K; Hess D; Bertz J; Langsam B; Aemisegger C; Ziegler U; Born W; Fuchs B
Biochim Biophys Acta; 2013 Aug; 1832(8):1173-82. PubMed ID: 23528710
[TBL] [Abstract][Full Text] [Related]
14. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
[TBL] [Abstract][Full Text] [Related]
15. Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.
Xiong S; Tu H; Kollareddy M; Pant V; Li Q; Zhang Y; Jackson JG; Suh YA; Elizondo-Fraire AC; Yang P; Chau G; Tashakori M; Wasylishen AR; Ju Z; Solomon H; Rotter V; Liu B; El-Naggar AK; Donehower LA; Martinez LA; Lozano G
Proc Natl Acad Sci U S A; 2014 Jul; 111(30):11145-50. PubMed ID: 25024203
[TBL] [Abstract][Full Text] [Related]
16. miR-365 functions as a tumor suppressor by directly targeting CYR61 in osteosarcoma.
Xu Y; Chu H; Zhou Y; Wang J; Dong C; Yin R
Biomed Pharmacother; 2018 Feb; 98():531-537. PubMed ID: 29287201
[TBL] [Abstract][Full Text] [Related]
17. MiR-216b inhibits osteosarcoma cell proliferation, migration, and invasion by targeting Forkhead Box M1.
Wang W; Guo Z; Yu H; Fan L
J Cell Biochem; 2019 Apr; 120(4):5435-5443. PubMed ID: 30302807
[TBL] [Abstract][Full Text] [Related]
18. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage.
Berman SD; Calo E; Landman AS; Danielian PS; Miller ES; West JC; Fonhoue BD; Caron A; Bronson R; Bouxsein ML; Mukherjee S; Lees JA
Proc Natl Acad Sci U S A; 2008 Aug; 105(33):11851-6. PubMed ID: 18697945
[TBL] [Abstract][Full Text] [Related]
19. Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.
Zhou R; Xu A; Gingold J; Strong LC; Zhao R; Lee DF
Trends Pharmacol Sci; 2017 Oct; 38(10):908-927. PubMed ID: 28818333
[TBL] [Abstract][Full Text] [Related]
20. The DNA helicase recql4 is required for normal osteoblast expansion and osteosarcoma formation.
Ng AJ; Walia MK; Smeets MF; Mutsaers AJ; Sims NA; Purton LE; Walsh NC; Martin TJ; Walkley CR
PLoS Genet; 2015 Apr; 11(4):e1005160. PubMed ID: 25859855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
